Risk and protective factors of ovarian cancer
Authors:
Luděk Záveský 1; Eva Jandáková 2; Radovan Turyna 3
Authors place of work:
Ústav biologie a lékařské genetiky, 1. lékařská fakulta Univerzity Karlovy, Praha
1; Ústav patologie, Fakultní nemocnice Brno
2; Ústav pro péči o matku a dítě, Praha
3
Published in the journal:
Prakt Gyn 2015; 19(3): 166-171
Category:
Oncogynecology: Original Article
Summary
The causes of the sporadic incidence of ovarian cancer (85% of the cases) still remain to be resolved. The remaining cases may result from genetic alterations in genome, chromosomes, genes and regulation factors. Germline mutations of the BRCA1/2 and DNA mismatch repair genes may cause hereditary forms of ovarian cancer. Epidemiological studies still have failed to find any generally applicable protective factor. Somewhat protective effects have been found for healthy lifestyle with sufficient fruits and vegetables consumption and limited red meat consumption and enough physical activity. Multiparity, breastfeeding, less ovulation years, tubal ligation and using hormonal contraception (however, this increases risk for breast cancer) have been further reported to decrease the risk for ovarian cancer. In addition to mutations, high consumption of sugar, obesity, later age in menopause, in vitro fertilization, hormone replacement therapy and nulliparity are suspected to increase the risk for ovarian cancer.
Key words:
ovarian carcinoma – risk factors – protective factors – BRCA1/2 – hormonal contraception – HRT
Zdroje
1. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita: 2005. Dostupné z WWW: <http://www.svod.cz>.
2. Záveský L, Jandáková E, Turyna R et al. Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study. Pathol Oncol Res 2015; 21(4):1027–1035.
3. Záveský L, Jandáková E, Turyna R et al. New perspectives in diagnosis of gynaecological cancers: Emerging role of circulating microRNAs as novel biomarkers. Neoplasma 2015; 62(4): 509–520.
4. Kan CWS, Howell VM, Hahn MA, Marsh DJ. Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. Genes Chromosomes Cancer 2015; 54(1): 1–19.
5. McCann GA, Eisenhauer EL. Hereditary cancer syndromes with high risk of endometrial and ovarian cancer: Surgical options for personalized care. J Surg Oncol 2015; 111(1): 118–124.
6. George J, Alsop K, Etemadmoghadam D et al. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res 2013; 19(13): 3474–3484.
7. Kamieniak MM, Munoz-Repeto I, Rico D et al. DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas. Br J Cancer 2013; 108(8): 1732–1742.
8. Pennington KP, Swisher EM. Hereditary ovarian cancer: Beyond the usual suspects. Gynecol Oncol 2012; 124(2): 347–353.
9. Xiao X, Melton DW, Gourley C. Mismatch repair deficiency in ovarian cancer – Molecular characteristics and clinical implications. Gynecol Oncol 2014; 132(2): 506–512.
10. Merritt MA, Poole EM, Hankinson SE et al. Dairy food and nutrient intake in different life periods in relation to risk of ovarian cancer. Cancer Causes Control 2014; 25(7): 795–808.
11. Liu J, Tang W, Sang L et al. Milk, yogurt, and lactose intake and ovarian cancer risk: A meta-analysis. Nutr Cancer 2015; 67(1): 68–72.
12. Obon-Santacana M, Peeters PHM, Freisling H et al. Dietary intake of acrylamide and epithelial ovarian cancer risk in the european prospective investigation into cancer and nutrition (EPIC) cohort. Cancer Epidemiol Biomarkers Prev 2015; 24(1):291–297.
13. Kelemen LE, Bandera EV, Terry KL et al. Recent alcohol consumption and risk of incident ovarian carcinoma: A pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. BMC Cancer 13:28. Dostupné z DOI: <http://dx.doi.org/10.1186/1471–2407–13–28>.
14. King MG, Olson SH, Paddock L et al. Sugary food and beverage consumption and epithelial ovarian cancer risk: A population-based case-control study. BMC Cancer 13:94. Dostupné z DOI: <http://dx.doi.org/10.1186/1471–2407–13–94>.
15. Tasevska N, Jiao L, Cross AJ et al. Sugars in diet and risk of cancer in the NIH-AARP Diet and Health Study. Int J Cancer 2012; 130(1): 159–169.
16. Xie J, Poole EM, Terry KL et al. A prospective cohort study of dietary indices and incidence of epithelial ovarian cancer. J Ovarian Res 2015; 7: 112. Dostupné z DOI: <http://dx.doi.org/10.1186/s13048–014–0112–4>.
17. Chandran U, Bandera EV, Williams-King MG et al. Healthy eating index and ovarian cancer risk. Cancer Causes Control 2011; 22(4):563–751.
18. Thomson CA, Crane TE, Wertheim BC et al. Diet Quality and Survival After Ovarian Cancer: Results From the Women's Health Initiative. J Natl Cancer Inst 2014; 106(11). pii: dju314. Dostupné z DOI: <http://dx.doi.org/10.1093/jnci/dju314>.
19. Cassidy A, Huang T, Rice MS et al. Intake of dietary flavonoids and risk of epithelial ovarian cancer. Am J Clin Nutr 2014; 100(5): 1344–1351.
20. Braem MGM, Onland-Moret NC, Schouten LJ et al. Coffee and tea consumption and the risk of ovarian cancer: A prospective cohort study and updated meta-analysis. Am J Clin Nutr 2012; 95(5): 1172–1181.
21. Crane TE, Khulpateea BR, Alberts DS et al. Dietary intake and ovarian cancer risk: A systematic review. Cancer Epidemiol Biomarkers Prev 2014; 23(2): 255–273.
22. Merritt MA, Riboli E, Weiderpass E et al. Dietary fat intake and risk of epithelial ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol 2014; 38(5): 528–537.
23. Jiang PY, Jiang ZB, Shen KX et al. Fish intake and ovarian cancer risk: A meta-analysis of 15 case-control and cohort studies. PLoS ONE 2014; 9(4): e94601. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0094601>.
24. Psaltopoulou T, Kosti RI, Haidopoulos D et al. Olive oil intake is inversely related to cancer prevalence: A systematic review and a meta-analysis of 13800 patients and 23340 controls in 19 observational studies. Lipids Health Dis 2011; 10: 127. Dostupné z DOI: <http://dx.doi.org/10.1186/1476–511X-10–127>.
25. Neill AS, Ibiebele TI, Lahmann PH et al. Dietary phyto-oestrogens and the risk of ovarian and endometrial cancers: Findings from two Australian case-control studies. Br J Nutr 2014; 111(8): 1430–1440.
26. Lee AH, Su D, Pasalich M et al. Soy and isoflavone intake associated with reduced risk of ovarian cancer in southern Chinese women. Nutr Res 2014; 34(4):302–307.
27. Kang HB, Zhang YF, Yang JD et al. Study on soy isoflavone consumption and risk of breast cancer and survival. Asian Pac J Cancer Prev 2012; 13(3): 995–998.
28. Hedelin M, Lo M, Andersson TML et al. Dietary phytoestrogens and the risk of ovarian cancer in the women's lifestyle and health cohort study. Cancer Epidemiol Biomarkers Prev 2011; 20(2): 308–317.
29. Morimoto Y, Maskarinec G, Park SY et al. Dietary isoflavone intake is not statistically significantly associated with breast cancer risk in the Multiethnic Cohort. Br J Nutr 2014; 112(6): 976–983.
30. Lee AH, Pasalich M, Su D et al. Mushroom intake and risk of epithelial ovarian cancer in Southern Chinese women. Int J Gynecol Cancer 2013; 23(8): 1400–1405.
31. Tang L, Lee AH, Su D et al. Fruit and vegetable consumption associated with reduced risk of epithelial ovarian cancer in southern Chinese women. Gynecol Oncol 2014; 132(1): 241–247.
32. Lee AH, Su D, Pasalich M et al. Preserved foods associated with increased risk of ovarian cancer. Gynecol Oncol 2013; 129(3): 570–573.
33. Di Maso M, Talamini R, Bosetti C et al. Red meat and cancer risk in a network of case-control studies focusing on cooking practices. Ann Oncol 2013; 24(12): 3107–3112.
34. Aschebrook-Kilfoy B, Ward MH, Gierach GL et al. Epithelial ovarian cancer and exposure to dietary nitrate and nitrite in the NIH-AARP Diet and Health Study. Eur J Cancer Prev 2012; 21(1): 65–72.
35. Gram IT, Lukanova A, Brill I et al. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. Int J Cancer 2012; 130(9): 2204–2210.
36. Calle EE, Gapstur SM, Patel AV et al. Ovarian cancer and smoking: Individual participant meta-analysis including 28 114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol 2012; 13(9): 946–956.
37. Shah MM, Erickson BK, Matin T et al. Diabetes mellitus and ovarian cancer: More complex than just increasing risk. Gynecol Oncol 2014; 135(2): 273–277.
38. Poorolajal J, Jenabi E, Masoumi SZ. Body mass index effects on risk of Ovarian cancer: A meta-analysis. Asian Pac J Cancer Prev 2014; 15(18): 7665–7671.
39. Moorman PG, Jones LW, Akushevich L et al. Recreational Physical Activity and Ovarian Cancer Risk and Survival. Ann Epidemiol 2011; 21(3): 178–187.
40. Huang Z, Gao Y, Wen W et al. Contraceptive methods and ovarian cancer risk among Chinese women: A report from the Shanghai Women's Health Study. Int J Cancer 2015; 137(3): 607–614.
41. Ness RB, Dodge RC, Edwards RP et al. Contraception Methods, Beyond Oral Contraceptives and Tubal Ligation, and Risk of Ovarian Cancer. Ann Epidemiol 2011; 21(3): 188–196.
42. Gierisch JM, Coeytaux RR, Urrutia RP et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: A systematic review. Cancer Epidemiol Biomarkers Prev 2013; 22(11): 1931–1943.
43. Charlton BM, Rich-Edwards JW, Colditz GA et al. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses' Health Study: Prospective cohort study. BMJ 2014; 349: g6356. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.g6356>.
44. Van Leeuwen FE, Klip H, Mooij TM et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod 2011; 26(12): 3456–3465.
45. Li Y., Zhao J., Zhang, Q. et al. Does ovarian stimulation for IVF increase gynaecological cancer risk? A systematic review and meta-analysis. Reprod Biomed Online 2015; 31(1): 20–29..
46. Madsen C, Baandrup L, Dehlendorff C et al. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: A nationwide case-control study. Acta Obstet Gynecol Scand 2015; 94(1): 86–94.
47. Feng LP, Chen HL, Shen MY. Breastfeeding and the Risk of Ovarian Cancer: A Meta-Analysis. J Midwifery Womens Health 2014; 59(4): 428–437.
48. Bodelon C, Wentzensen N, Schonfeld SJ et al. Hormonal risk factors and invasive epithelial ovarian cancer risk by parity. Br J Cancer 2013; 109(3): 769–776.
49. Beral V, Bull D, Green J et al. Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369(9574): 1703–1710.
50. Morch LS, Lokkegaard E, Andreasen AH et al. Hormone Therapy and Ovarian Cancer. JAMA 2009; 302(3): 298–305.
51. Camargo MC, Stayner LT, Straif K et al. Occupational exposure to asbestos and ovarian cancer: A meta-analysis. Environ Health Perspect 2011; 119(9): 1211–1217.
52. Le ND, Leung A, Brooks-Wilson A et al. Occupational exposure and ovarian cancer risk. Cancer Causes Control 2014; 25(7): 829–841.
Štítky
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineČlánok vyšiel v časopise
Practical Gynecology
2015 Číslo 3
Najčítanejšie v tomto čísle
- Ocular indications for caesarean section
- Pelvic congestion syndrome and its treatment
- Dydrogesterone – clinical benefits of its metabolic neutrality
- How to correctly proceed in cases of suspicions of rape or sexual abuse